Back to products
Vidalista 20 mg Tablet
Original price was: ₱ 110.00.₱ 85.00Current price is: ₱ 85.00.Box
Palnat 125 mg Capsule
Brand Name: Palnat
Molecule: Palbociclib
Strength: 125 mg
Quantity: 21 Capsules
Form: Capsule
Packaging Type: Bottle
Manufacturer/Marketed By: Natco Pharma
Country of Origin: India
Please fill in the details below, and we’ll get back to you as soon as possible
Similar Products:
| Image | Product | Manufacturer / Marketed By | Price |
|---|---|---|---|
 | LuciPalbo 125 mg Capsule | Lucius Pharma | Ask for Price |
 | Ibrance 125 mg Capsule | Pfizer | Ask for Price |
| Palboxen 125 mg Capsule | Everest Pharma | Ask for Price |
Description
Palnat 125 mg Capsule contains Palbociclib, a CDK4/6 inhibitor used in combination with hormonal therapies for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. It slows cancer cell growth and improves progression-free survival in eligible patients. Palnat is an oral targeted therapy prescribed under oncologist supervision.
Benefits
-
Prolongs progression-free survival significantly
-
Oral tablet allows convenient home-based treatment
-
Enhances effectiveness of hormone therapies
-
Delays need for chemotherapy
-
Well-studied in first-line and second-line settings
Indications and Usage
Palnat is indicated for the treatment of:
-
Hormone Receptor–positive (HR+), HER2–negative:
-
Advanced or metastatic breast cancer
-
In combination with:
-
Letrozole as initial endocrine-based therapy in postmenopausal women
-
Fulvestrant in patients with disease progression after hormone therapy
-
-
Must be used under strict oncologist supervision with routine blood monitoring.
How it Works
Palbociclib selectively inhibits CDK4 and CDK6, proteins responsible for promoting cell division in hormone-sensitive breast cancers. By blocking these, it halts the cancer cell cycle, slowing tumor growth and enhancing the effect of hormone therapies.
Dosage & Administration
-
Typical dose: 125 mg once daily for 21 days, followed by 7 days off (28-day cycle)
-
Should be taken with food at the same time every day
-
Swallow the capsule whole — do not open, crush, or chew
-
Continue endocrine therapy (letrozole or fulvestrant) as advised
-
Regular blood tests are required to monitor white cell counts and liver function
-
Dose may be adjusted based on side effects or blood test results
Side Effects
Common side effects:
-
Low white blood cell count (neutropenia)
-
Infections
-
Fatigue
-
Nausea
-
Diarrhea
-
Hair thinning
-
Mouth sores
-
Anemia
Serious side effects:
-
Febrile neutropenia (fever with low WBCs)
-
Severe infections
-
Lung inflammation (rare)
-
Liver enzyme elevation
Warning and Precaution
-
Not safe during pregnancy or breastfeeding
-
May suppress immunity — avoid contact with infections
-
Use contraception during and for 3 weeks after last dose (women), 14 weeks (men)
-
Monitor for signs of lung inflammation, bleeding, or fatigue
-
Avoid grapefruit and grapefruit juice
-
Inform your doctor about all ongoing medications
Related Products
Related Posts:
Ruxolitinib Tablets Receive FDA Approval for Hematologic Malignancies
The U.S. Food and Drug Administration (FDA) has approved Ruxolitinib tablets for the treatment of certain hematologic malignancies, marking another
READ MORE »May 18, 2026
Tovorafenib Approved in Europe for Children with BRAF-Altered Low-Grade Glioma
n Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 14, 2026.n n This marks an important
READ MORE »May 14, 2026
FDA Approves Vepdegestrant for ER+/HER2–, ESR1-Mutated Breast Cancer: A New Targeted Option
Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 6, 2026. Breast cancer treatment continues to evolve
READ MORE »May 6, 2026
Only logged in customers who have purchased this product may leave a review.
Reviews
Clear filtersThere are no reviews yet.